Frezent Biological

Despite advances in cancer therapy, recurrence remains a major unmet need and a leading cause of cancer-related mortality. More than half of patients relapse and succumb to the disease in less than two years. Frezent is developing a pan-cancer platform of first-in-class monoclonal antibodies and dual-targeted biologics designed to prevent reactivation of stem-cell-like dormant cancer cells—the source of deadly recurrence. Frezent's lead candidate has shown compelling in vivo efficacy in head and neck squamous cell carcinoma, demonstrating the ability to prevent tumor regrowth after chemotherapy. Led by a strong team of founders and backed by seasoned biotech executives, Frezent is working toward its mission: to ensure a future where long-lasting remission is a reality for all cancer patients.